Organon's VTAMA Shows Early Efficacy in Young Atopic Dermatitis Patients — Organon & Co.

Event summary

Organon presented pooled Phase 3 data for VTAMA cream at the 2026 AAD Annual Meeting, showing early skin clearance and itch improvement in atopic dermatitis patients as young as 2 years old.
The analysis of ADORING 1 and ADORING 2 trials demonstrated significant improvements in vIGA-AD, EASI75, and PP-NRS response rates as early as week 1.
VTAMA cream achieved a 45.9% vIGA-AD response rate at week 8 compared to 15.9% for the vehicle group.
The treatment was well-tolerated, with the most common adverse events being folliculitis, headache, upper respiratory tract infection, and nasopharyngitis.

The big picture

Organon's VTAMA cream is positioned as a dual-purpose treatment for both plaque psoriasis and atopic dermatitis, addressing a significant unmet need in pediatric dermatology. The early efficacy data in young patients could bolster its competitive edge in a market dominated by older therapies. With the FDA approvals already in place, Organon is well-positioned to capitalize on these findings to drive further adoption and revenue growth.

What we're watching

Pediatric Market Expansion: How Organon will leverage these results to expand VTAMA's market share in pediatric atopic dermatitis.
Competitive Positioning: Whether VTAMA can differentiate itself from existing treatments like topical corticosteroids and JAK inhibitors.
Regulatory Approvals: The pace at which Organon can secure additional regulatory approvals for VTAMA in other indications or regions.